Sanofi and Alexandria Real Estate Equities could exit the chronic disease therapeutics developer, which has set the range for an offering that could raise up to $170m.
Dice Molecules, the US-based oral therapeutic developer backed by pharmaceutical firm Sanofi and life sciences real estate investment trust Alexandria Real Estate Equities, set terms yesterday for an initial public offering that could raise $170m. The company plans to list 10 million shares on the Nasdaq Global Market and has set a price range of…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.